Molecular Partners AG (XSWX:MOLN) Share Price

Company Profile

Business description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Contact
Wagistrasse 14
Schlieren
Zurich8952
CHE
T: +41 447557700
https://www.molecularpartners.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
167

Recommended

Current operating conditions are challenging but over the long-term prospects are better.

Johannes Faul | 25 February 2025

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Joseph Taylor | 25 February 2025

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar | 25 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,477.30	20.70	-0.24%
CAC 40	8,143.92	92.85	1.15%
DAX 40	22,794.11	383.84	1.71%
Dow JONES (US)	43,412.50	208.66	-0.48%
FTSE 100	8,731.46	62.79	0.72%
HKSE	23,787.93	753.91	3.27%
NASDAQ	19,089.08	62.69	0.33%
Nikkei 225	38,142.37	95.42	-0.25%
NZX 50 Index	12,452.46	145.19	1.18%
S&P 500	5,957.19	1.94	0.03%
S&P/ASX 200	8,240.70	11.20	-0.14%
SSE Composite Index	3,380.21	34.17	1.02%